Zarauza Santoveña A, García Meseguer C, Martínez Mejía S, Alonso Melgar Á, Fernández Camblor C, Melgosa Hijosa M, Peña Carrión A, Espinosa Román L
Servicio de Nefrología Pediátrica, Hospital Universitario La Paz, Madrid, Spain.
Servicio de Nefrología Pediátrica, Hospital Universitario La Paz, Madrid, Spain.
Transplant Proc. 2015 Jan-Feb;47(1):62-6. doi: 10.1016/j.transproceed.2014.11.020.
Polyomavirus BK (BKV) is a common complication after renal transplantation and an important cause of graft loss. The purpose of this study was to determine the incidence of BKV infection (viremia) in our population and to describe clinical features, global outcomes, and potential correlations with clinical or epidemiologic factors.
This retrospective single-center study included 84 pediatric recipients of kidney transplantation from January 2006 to September 2012. BKV infection screening consisted of periodic determination of decoy cells in urine samples, confirmed by means of quantitative polymerase chain reaction test in blood.
Twenty-two patients (26%) developed BKV viremia. BKV replication appeared early after renal transplantation (median, 2 months). One-third of patients remained asymptomatic, and 27% presented elevated serum creatinine. Immunosuppression was reduced in 90% of patients, and 83% achieved clearance of viremia within 6 months. There was only 1 case of histologically confirmed BKV nephropathy, which evolved to graft loss despite leflunomide, intravenous immunoglobulins, and mycophenolate discontinuation. Risk of BKV viremia was associated with younger age at transplantation (5.9 y vs 10.9 years; P = .001) and cadaveric donor (relative risk, 3.2; P < .05). BKV infection did not affect short-term renal function and graft survival.
BKV viremia is very common in the pediatric renal transplant population, especially in younger children and in those receiving a kidney from cadaveric donors. It develops in the 1st months after transplantation. Reduction of immunosuppression seems to be a good therapeutic option, with high rates of clearance of the infection, although the only patient with confirmed BKV nephropathy had poor outcome.
多瘤病毒BK(BKV)是肾移植术后常见的并发症,也是移植物丢失的重要原因。本研究旨在确定我们研究人群中BKV感染(病毒血症)的发生率,并描述其临床特征、总体结局以及与临床或流行病学因素的潜在相关性。
这项回顾性单中心研究纳入了2006年1月至2012年9月期间84例接受肾移植的儿科受者。BKV感染筛查包括定期检测尿液样本中的诱饵细胞,并通过血液定量聚合酶链反应试验进行确认。
22例患者(26%)发生了BKV病毒血症。BKV复制在肾移植后早期出现(中位时间为2个月)。三分之一的患者无症状,27%的患者血清肌酐升高。90%的患者免疫抑制得到降低,83%的患者在6个月内实现了病毒血症清除。仅有1例经组织学证实的BKV肾病病例,尽管停用了来氟米特、静脉注射免疫球蛋白和霉酚酸酯,但仍发展为移植物丢失。BKV病毒血症的风险与移植时年龄较小(5.9岁对10.9岁;P = 0.001)和尸体供体有关(相对风险,3.2;P < 0.05)。BKV感染不影响短期肾功能和移植物存活。
BKV病毒血症在儿科肾移植人群中非常常见,尤其是在年幼儿童和接受尸体供肾者中。它在移植后的头几个月内发生。降低免疫抑制似乎是一种良好的治疗选择,感染清除率较高,尽管唯一经证实的BKV肾病患者预后较差。